Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 240

1.

Preventing future cancers by testing women with ovarian cancer for BRCA mutations.

Kwon JS, Daniels MS, Sun CC, Lu KH.

J Clin Oncol. 2010 Feb 1;28(4):675-82. doi: 10.1200/JCO.2008.21.4684. Epub 2009 Oct 19.

PMID:
19841329
2.

Expanding the criteria for BRCA mutation testing in breast cancer survivors.

Kwon JS, Gutierrez-Barrera AM, Young D, Sun CC, Daniels MS, Lu KH, Arun B.

J Clin Oncol. 2010 Sep 20;28(27):4214-20. doi: 10.1200/JCO.2010.28.0719. Epub 2010 Aug 23.

PMID:
20733129
4.

Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.

Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S, Offit K.

Clin Cancer Res. 2002 Dec;8(12):3776-81.

5.

Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.

Uyei A, Peterson SK, Erlichman J, Broglio K, Yekell S, Schmeler K, Lu K, Meric-Bernstam F, Amos C, Strong L, Arun B.

Cancer. 2006 Dec 15;107(12):2745-51.

6.

Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.

Anderson K, Jacobson JS, Heitjan DF, Zivin JG, Hershman D, Neugut AI, Grann VR.

Ann Intern Med. 2006 Mar 21;144(6):397-406.

PMID:
16549852
7.

BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.

Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, LaPolla J, Hoffman M, Martino MA, Wakeley K, Wilbanks G, Nicosia S, Cantor A, Sutphen R.

Cancer. 2005 Dec 15;104(12):2807-16.

8.

Founder BRCA 1 and 2 mutations among a consecutive series of Ashkenazi Jewish ovarian cancer patients.

Tobias DH, Eng C, McCurdy LD, Kalir T, Mandelli J, Dottino PR, Cohen CJ.

Gynecol Oncol. 2000 Aug;78(2):148-51.

PMID:
10926794
9.

A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer.

Eccleston A, Bentley A, Dyer M, Strydom A, Vereecken W, George A, Rahman N.

Value Health. 2017 Apr;20(4):567-576. doi: 10.1016/j.jval.2017.01.004. Epub 2017 Mar 3.

10.

Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer.

Loman N, Johannsson O, Kristoffersson U, Olsson H, Borg A.

J Natl Cancer Inst. 2001 Aug 15;93(16):1215-23.

PMID:
11504767
11.

Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history.

Berry DA, Parmigiani G, Sanchez J, Schildkraut J, Winer E.

J Natl Cancer Inst. 1997 Feb 5;89(3):227-38.

PMID:
9017003
12.

Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers.

Kwon JS, Tinker A, Pansegrau G, McAlpine J, Housty M, McCullum M, Gilks CB.

Obstet Gynecol. 2013 Jan;121(1):14-24. doi: http://10.1097/AOG.0b013e3182783c2f.

PMID:
23232752
13.

Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing.

Manchanda R, Legood R, Burnell M, McGuire A, Raikou M, Loggenberg K, Wardle J, Sanderson S, Gessler S, Side L, Balogun N, Desai R, Kumar A, Dorkins H, Wallis Y, Chapman C, Taylor R, Jacobs C, Tomlinson I, Beller U, Menon U, Jacobs I.

J Natl Cancer Inst. 2014 Nov 30;107(1):380. doi: 10.1093/jnci/dju380. Print 2015 Jan.

14.

Cost-effectiveness of population-based BRCA1/2 testing and ovarian cancer prevention for Ashkenazi Jews: a call for dialogue.

Rubinstein WS, Jiang H, Dellefave L, Rademaker AW.

Genet Med. 2009 Sep;11(9):629-39. doi: 10.1097/GIM.0b013e3181afd322.

PMID:
19606050
15.

BRCA-1 and BRCA-2 mutations as prognostic factors in clinical practice and genetic counselling.

Nicoletto MO, Donach M, De Nicolo A, Artioli G, Banna G, Monfardini S.

Cancer Treat Rev. 2001 Oct;27(5):295-304. Review.

PMID:
11871866
16.

The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews.

Hartge P, Struewing JP, Wacholder S, Brody LC, Tucker MA.

Am J Hum Genet. 1999 Apr;64(4):963-70.

17.

Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.

Chetrit A, Hirsh-Yechezkel G, Ben-David Y, Lubin F, Friedman E, Sadetzki S.

J Clin Oncol. 2008 Jan 1;26(1):20-5. doi: 10.1200/JCO.2007.11.6905.

PMID:
18165636
18.

Breast cancer susceptibility testing: past, present and future.

Goldberg JI, Borgen PI.

Expert Rev Anticancer Ther. 2006 Aug;6(8):1205-14. Review.

PMID:
16925486
19.

Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force.

Nelson HD, Huffman LH, Fu R, Harris EL; U.S. Preventive Services Task Force.

Ann Intern Med. 2005 Sep 6;143(5):362-79. Review. Erratum in: Ann Intern Med. 2005 Oct 4;143(7):547.

PMID:
16144895
20.

High frequency of BRCA1 and BRCA2 germline mutations in Ashkenazi Jewish ovarian cancer patients, regardless of family history.

Beller U, Halle D, Catane R, Kaufman B, Hornreich G, Levy-Lahad E.

Gynecol Oncol. 1997 Nov;67(2):123-6.

PMID:
9367693

Supplemental Content

Support Center